208 related articles for article (PubMed ID: 21070569)
1. Validity and reliability of the patient's perception of intensity of urgency scale in overactive bladder.
Cartwright R; Srikrishna S; Cardozo L; Robinson D
BJU Int; 2011 May; 107(10):1612-7. PubMed ID: 21070569
[TBL] [Abstract][Full Text] [Related]
2. Patient-selected goals in overactive bladder: a placebo controlled randomized double-blind trial of transdermal oxybutynin for the treatment of urgency and urge incontinence.
Cartwright R; Srikrishna S; Cardozo L; Robinson D
BJU Int; 2011 Jan; 107(1):70-6. PubMed ID: 20626389
[TBL] [Abstract][Full Text] [Related]
3. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J
BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
[TBL] [Abstract][Full Text] [Related]
4. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study.
Sand P; Zinner N; Newman D; Lucente V; Dmochowski R; Kelleher C; Dahl NV
BJU Int; 2007 Apr; 99(4):836-44. PubMed ID: 17187655
[TBL] [Abstract][Full Text] [Related]
5. Correlation between improvements in Overactive Bladder Symptom Score and health-related quality of life questionnaires in overactive bladder patients treated with an antimuscarinic drug.
Kubota Y; Kojima Y; Shibata Y; Imura M; Kohri K; Sasaki S
Neurourol Urodyn; 2011 Sep; 30(7):1309-14. PubMed ID: 21560155
[TBL] [Abstract][Full Text] [Related]
6. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T
Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
[TBL] [Abstract][Full Text] [Related]
7. Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.
Garely AD; Lucente V; Vapnek J; Smith N
Ann Pharmacother; 2007 Mar; 41(3):391-8. PubMed ID: 17341526
[TBL] [Abstract][Full Text] [Related]
8. Response to fesoterodine in patients with an overactive bladder and urgency urinary incontinence is independent of the urodynamic finding of detrusor overactivity.
Nitti VW; Rovner ES; Bavendam T
BJU Int; 2010 May; 105(9):1268-75. PubMed ID: 19889062
[TBL] [Abstract][Full Text] [Related]
9. [Urinary urgency].
MMW Fortschr Med; 2008 Jul; 150(28-31):58-9. PubMed ID: 19009709
[No Abstract] [Full Text] [Related]
10. Urgency assessment in the evaluation of overactive bladder (OAB).
Starkman JS; Dmochowski RR
Neurourol Urodyn; 2008; 27(1):13-21. PubMed ID: 17671973
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of overactive urinary bladder with imperative urinary incontinence in women].
Neĭmark AI; Riapolova MV; Mel'nik MA
Urologiia; 2010; (2):36-8. PubMed ID: 20967993
[TBL] [Abstract][Full Text] [Related]
12. Impact of convenience void in a bladder diary with urinary perception grade to assess overactive bladder symptoms: a community-based study.
Honjo H; Kawauchi A; Nakao M; Ukimura O; Kitakoji H; Miki T
Neurourol Urodyn; 2010 Sep; 29(7):1286-9. PubMed ID: 20878998
[TBL] [Abstract][Full Text] [Related]
13. Solifenacin treatment for overactive bladder in Hispanic patients: patient-reported symptom bother and quality of life outcomes from the VESIcare Open-Label Trial.
Capo' JP; Laramée C; Lucente V; Fakhoury A; Forero-Schwanhaeuser S
Int J Clin Pract; 2008 Jan; 62(1):39-46. PubMed ID: 18036164
[TBL] [Abstract][Full Text] [Related]
14. Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms.
Rovner ES; Kreder K; Sussman DO; Kaplan SA; Carlsson M; Bavendam T; Guan Z
J Urol; 2008 Sep; 180(3):1034-41. PubMed ID: 18639297
[TBL] [Abstract][Full Text] [Related]
15. Editorial comment on: Cizolirtine citrate is safe and effective for treating urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study.
Costantini E; Lazzeri M
Eur Urol; 2010 Jan; 57(1):152-3. PubMed ID: 19446952
[No Abstract] [Full Text] [Related]
16. Editorial comment on: Cizolirtine citrate is safe and effective to treat urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study.
Soljanik I
Eur Urol; 2010 Jan; 57(1):153. PubMed ID: 19446950
[No Abstract] [Full Text] [Related]
17. Idiopathic urgency urinary incontinence.
Keller DL
N Engl J Med; 2010 Dec; 363(27):2672; author reply 2672. PubMed ID: 21190469
[No Abstract] [Full Text] [Related]
18. Efficacy, tolerability and safety of propiverine hydrochloride in comparison to oxybutynin in children with urge incontinence due to overactive bladder: Results of a multicentre observational cohort study.
Alloussi S; Mürtz G; Braun R; Gerhardt U; Heinrich M; Hellmis E; Horn W; Marschall-Kehrel D; Niklas K; Raabe M; Rössler T; Seibt B; Siemer S; Schultz-Lampel D; Walter H; Wiedeking B; Alloussi S; Bock P; Strugala G; Madersbacher H
BJU Int; 2010 Aug; 106(4):550-6. PubMed ID: 20002668
[TBL] [Abstract][Full Text] [Related]
19. Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine.
Coyne KS; Elinoff V; Gordon DA; Deng DY; Brodsky M; Glasser DB; Jumadilova Z; Carlsson M
Int J Clin Pract; 2008 Jun; 62(6):925-31. PubMed ID: 18479285
[TBL] [Abstract][Full Text] [Related]
20. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M
Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
